ReviewJournal of clinical microbiology2019
Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.
Review in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: a systematic review and meta-analysis.Emerging microbes & infections · 2022Pooled it
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.Lancet (London, England) · 2022Pooled it
- A Systematic Review on Antimicrobial Resistance amongThe American journal of tropical medicine and hygiene · 2020Pooled it
- Large-scale assessment of antimicrobial resistance marker databases for genetic phenotype prediction: a systematic review.The Journal of antimicrobial chemotherapy · 2020Pooled it
- Real-World Effectiveness of Intravenous and Oral Antibiotic Stepdown Strategies for Gram-Negative Complicated Urinary Tract Infection With Bacteremia.Open forum infectious diseases · 2024Trial
- Oral β-Lactams, Fluoroquinolones, or Trimethoprim-Sulfamethoxazole for Definitive Treatment of UncomplicatedOpen forum infectious diseases · 2024Trial
- Biocontrol of Staphylococcus aureus in dairy products using lytic bacteriophage UHP46: efficacy in milk, cheese, and yogurt.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Article
- Rising Carbapenem MICs and Clinical Dose Optimization: Bridging Resistance Surveillance and Pharmacokinetic/Pharmacodynamic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- Discovery of potent low-toxicity antimicrobial peptides through diffusion modeling.Nature communications · 2026Article
- Urine antibiogram and antimicrobial susceptibility pattern in a provincial hospital of Nepal: a cross-sectional study.BMC infectious diseases · 2026Article
- Slow Thinking for Fast Results: Reclaiming Analytical Reasoning in Antimicrobial Susceptibility Test Interpretation.Open forum infectious diseases · 2026Article
- Assessment of the revision of the 2025 CLSI breakpoints for the interpretation of minocycline susceptibility forMicrobiology spectrum · 2026Article
- Identification of gut microbiota features of diarrheic calves using the full-length 16S rRNA gene amplicon sequencing and machine learning.Animal microbiome · 2026Article
- Comparison and validation of multiple machine learning algorithms for predicting MDRO infection in catheter-related bloodstream patients: a multicenter cohort study.Microbiology spectrum · 2026Article
- Article
- Clinical Outcomes in Adult Patients Receiving Definitive Cefazolin Therapy for Community-Acquired Enterobacterales Bacteremias across Minimum Inhibitory Concentration Breakpoints.The Canadian journal of hospital pharmacy · 2026Article
- Prevalence and Antimicrobial Resistance ofInfection and drug resistance · 2026Article
- Precision diagnosis of preoperative infection in urolithiasis: integrating targeted next-generation sequencing for enhanced accuracy-a multicenter cohort study.BMC infectious diseases · 2025Article
- No Evidence of Temperature-Driven Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2025Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Clinical and Laboratory Standards Institute (CLSI) has revised several breakpoints since 2010 for bacteria that grow aerobically. In 2019, these revisions include changes to the ciprofloxacin and levofloxacin breakpoints for the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.